Fate Therapeutics Q2 2024 Adj EPS $(0.33) Beats $(0.48) Estimate, Sales $6.80M Beat $1.41M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fate Therapeutics (NASDAQ:FATE) reported Q2 2024 adjusted EPS of $(0.33), beating the $(0.48) estimate. Sales were $6.80M, surpassing the $1.41M estimate and marking a 628.83% increase from the same period last year.
August 13, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fate Therapeutics reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.33) beating the $(0.48) estimate and sales of $6.80M surpassing the $1.41M estimate. This represents a significant 628.83% increase in sales compared to the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year increase in sales, is likely to positively impact Fate Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100